Recent Updates
Recently added Catalysts

catheter lock

Phase 3

Central Line Associated Blood Stream Infections (CLABSI) | Small molecule | Infectious Disease |CorMedix Inc.|Last Updated: Aug 5, 2026

Target and mechanism

ModalitySmall molecule

Also known as (taurolidine and heparin) catheter lock solution

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindACTIVE_CONTROLLEDDMC
Total Trials1
Total Enrollment200

FDA Designations

No designations recorded

Clinical trial landscape

catheter lock · 1 trial · 1 indication

Phase 3 1
NCT06822426Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)Central Line Associated Blood Stream Infections (CLABSI)
RECRUITING200 Analytics
PHASE3RECRUITING
Comparing The Safety And Efficacy Of DEFENCATH® In Reducing Central-Line Bloodstream Infections (CLABSIs) In Adults Receiving Total Parenteral Nutrition Through A Central Venous Catheter (CVC)
Central Line Associated Blood Stream Infections (CLABSI)
NCT06822426200
Unlock trial analytics

Study Endpoints

Primary Endpoints

Comparison between treatment groups of proportion of participants who experience a Central Line-Associated Bloodstream Infections (CLABSI) within 12 months of the start of the study
Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)

The proportion of participants who remain infection-free in the treatment groups will be compared, censoring participants who do not experience a CLABSI within 9 months, but fail to complete the 12 month follow-up period of the study.

Secondary Endpoints

Incidence of AEs, SAEs, treatment-emergent adverse events (TEAEs)
Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
Incidence of changes in laboratory evaluations, vital signs, or physical exam findings
Self-administered by participants (or a designated caregiver) per the participants regular TPN/ line access schedule, through study completion (up to 12 months)
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposePREVENTION

Treatment Arms

ArmTypeDescription
DefenCath®EXPERIMENTAL -
ControlACTIVE_COMPARATOR -

Interventions

NameTypeDescription
(taurolidine and heparin) catheter lock solutionDRUGfor central venous catheter installation use
HeparinDRUGHeparin
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites22

1. Participants who are resident within the US and Türkiye. 2. Participants who are male or female, aged ≥18 years at the time of consent. 3. Participants must sign and provide informed consent. 4. Participants who have a permanent tunneled CVC or permanent peripherally inserted central catheter (PI...

Countries:United StatesTurkey (Türkiye)
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWAug 5, 2026NCT06822426lastUpdatePostDate: changed
LOWJul 21, 2026NCT06822426lastUpdatePostDate: changed

Frequently asked questions about catheter lock

What is catheter lock used for?

Catheter lock is used for reducing Central Line Associated Blood Stream Infections (CLABSI) in adults receiving total parenteral nutrition through a central venous catheter. It is an investigational taurolidine and heparin catheter lock solution being studied in a Phase 3 clinical trial.

What does catheter lock target?

Catheter lock contains taurolidine and heparin. Taurolidine is an antimicrobial agent that targets and neutralizes bacterial toxins and prevents microbial adherence, while heparin acts as an anticoagulant to maintain catheter patency. Together they work to reduce the risk of catheter-related bloodstream infections.

Who makes catheter lock?

CorMedix Inc. (ticker: CRMD) is developing catheter lock, a taurolidine and heparin catheter lock solution. The company is conducting a Phase 3 clinical trial to evaluate its safety and efficacy in reducing Central Line Associated Blood Stream Infections (CLABSI).

What phase is catheter lock in?

Catheter lock is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 3 trial is actively recruiting participants to assess its effectiveness in reducing CLABSI in adults receiving total parenteral nutrition.

What clinical trials is catheter lock in?

Catheter lock is being studied in one Phase 3 clinical trial, NCT06822426. This randomized, double-blind, active-controlled study is recruiting 200 adults aged 18 years and older in the United States and Turkey. The trial compares the safety and efficacy of DEFENCATH in reducing central-line bloodstream infections.

Is catheter lock the same as DEFENCATH?

Yes, catheter lock is also known as DEFENCATH, a taurolidine and heparin catheter lock solution. The Phase 3 clinical trial NCT06822426 evaluates DEFENCATH in reducing Central Line Associated Blood Stream Infections (CLABSI) in adults receiving total parenteral nutrition through a central venous catheter.